Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification

Fig. 5

MP-IF panels for ICP combinations stratifying NSCLC patients. a-c Summarizing graph of P-values generated from K-M survival analyses (left), of ICP alone, and in combination with each other and with CD3 TILs, where significance indicates positive associations of combinations with OS. From top to bottom, panels interrogate combinations of CD3+ TILs and ICPs (a) TIM-3, CD26 and CD39, (b) TIM-3, BTLA and LAG-3, and (c) 2B4, PD-1, and CD57. K-M plots (right) illustrate similarities of curves of ICP combinations ± CD3 co-labeling. The number of patients (n) for each group is given on K-M curves, and others are either previously reported in Fig. 3, or are (high and low, respectively): CD26 n = 34hi, 32lo, CD39 n = 32hi, 26lo, CD26-CD39 n = 37hi, 35lo, TIM-3-CD26 n = 35hi, 37lo, TIM-3-LAG-3 n = 36hi, 32lo, TIM-3-BTLA n = 39hi, 31lo, 2B4 n = 31hi, 33lo, CD57 n = 29hi, 34lo, 2B4-CD57 n = 30hi, 35lo, PD-1-CD57 n = 27hi, 38lo, and 2B4-PD-1 n = 24hi, 44lo; associated confidence intervals are listed in Additional file 1: Table S12. Algorithm design, normalization and analyses were performed by two independent operators. Representative images of CD3-ICP colocalization-dense core areas can be found in Additional file 1: Figure S6. hi, high marker expression, lo, low marker expression; P, Log-rank test; ns, not significant; * P < 0.05; ** P < 0.01; HR, hazard ratio (Log-rank); CI, confidence interval of ratio

Back to article page